CHEST 2022
Dupilumab Reduces Oral Corticosteroid Use in OCS-Dependent Severe Asthma
Post hoc analysis of the VENTURE/TRAVERSE trials assessed dupilumab efficacy in patients with severe asthma requiring varying levels of oral corticosteroids at baseline.